Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Stephen G Noorduyn; Karissa Johnston; Kathy Osenenko; Niroshan Sriskandarajah; Alain Gendron; Lawrence Mbuagbaw

doi:10.1183/23120541.00465-2021

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

ERJ Open Res. 2021 Dec 6;7(4):00465-2021. doi: 10.1183/23120541.00465-2021. eCollection 2021 Oct.

Authors

Stephen G Noorduyn^{1

2}, Karissa Johnston^{3

4}, Kathy Osenenko³, Niroshan Sriskandarajah¹, Alain Gendron⁵, Lawrence Mbuagbaw²

Affiliations

¹ AstraZeneca Canada Ltd, Mississauga, ON, Canada.
² Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
³ Broadstreet HEOR, Vancouver, BC, Canada.
⁴ Memorial University, St John's, NL, Canada.
⁵ Dept of Medicine, University of Montreal, Montreal, QC, Canada.

Abstract

Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.